TY - JOUR T1 - Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy JF - Anticancer Research JO - Anticancer Res SP - 6567 LP - 6573 DO - 10.21873/anticanres.13872 VL - 39 IS - 12 AU - MASATAKA ONEYAMA AU - NAOYA SAKAMOTO AU - NAOHIDE OUE AU - YAYOI KIMURA AU - YUKIHIKO HIROSHIMA AU - ITARU HASHIMOTO AU - KENTARO HARA AU - YUKIO MAEZAWA AU - KAZUKI KANO AU - TORU AOYAMA AU - HIROHITO FUJIKAWA AU - TAKANOBU YAMADA AU - HIROSHI TAMAGAWA AU - NAOTO YAMAMOTO AU - TAKASHI OGATA AU - HARUHIKO CHO AU - HIROYUKI ITO AU - NORIO YUKAWA AU - MANABU SHIOZAWA AU - TAKAKI YOSHIKAWA AU - SOICHIRO MORINAGA AU - YASUSHI RINO AU - MUNETAKA MASUDA AU - YOHEI MIYAGI AU - WATARU YASUI AU - TAKASHI OSHIMA Y1 - 2019/12/01 UR - http://ar.iiarjournals.org/content/39/12/6567.abstract N2 - Background/Aim: The KIAA1199 gene has been associated with cancer-cell proliferation, but its functions remain poorly studied. Here, we examined the clinical significance of the KIAA1199 mRNA levels in locally advanced gastric cancer (GC). Materials and Methods/Results: Using samples from 254 patients with stage II/III GC, we found significantly higher KIAA1199 levels in cancerous tissues compared to adjacent normal mucosa (ANM). There was no significant relationship between KIAA1199 expression and clinical features. Although overall survival rates (OSR) of patients, who underwent surgery did not correlate with KIAA1199 expression, patients who underwent adjuvant chemotherapy with S-1 and had high KIAA1199 levels displayed significantly lower OSR. KIAA1199 knock down (KIAA1199-KD) suppressed proliferation, invasiveness, and sensitivity of GC cells to 5-fluorouracil (5-FU). Conclusion: KIAA1199 expression appears to be a promising prognostic marker in patients with locally advanced GC, who underwent postoperative adjuvant chemotherapy with S-1. KIAA1199 may represent a novel target for GC pharmacotherapy. ER -